ARK Genomic Revolution ETF (BATS:ARKG – Get Free Report) saw unusually large options trading on Tuesday. Stock traders acquired 32,950 call options on the company. This is an increase of approximately 125% compared to the average daily volume of 14,663 call options.
Hedge Funds Weigh In On ARK Genomic Revolution ETF
Hedge funds have recently made changes to their positions in the company. JPMorgan Chase & Co. grew its position in shares of ARK Genomic Revolution ETF by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock valued at $75,655,000 after purchasing an additional 698,701 shares in the last quarter. Atom Investors LP grew its position in shares of ARK Genomic Revolution ETF by 15.2% in the third quarter. Atom Investors LP now owns 49,131 shares of the company’s stock valued at $1,258,000 after purchasing an additional 6,496 shares in the last quarter. Barclays PLC grew its position in shares of ARK Genomic Revolution ETF by 252.7% in the third quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after purchasing an additional 204,283 shares in the last quarter. National Bank of Canada FI grew its position in shares of ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after purchasing an additional 920 shares in the last quarter. Finally, Sanctuary Advisors LLC purchased a new stake in shares of ARK Genomic Revolution ETF in the second quarter valued at approximately $222,000.
ARK Genomic Revolution ETF Price Performance
Shares of ARK Genomic Revolution ETF stock traded up $5.88 during mid-day trading on Tuesday, reaching $29.49. 4,900,270 shares of the stock traded hands. The company has a fifty day moving average price of $25.66 and a 200-day moving average price of $25.29.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
See Also
- Five stocks we like better than ARK Genomic Revolution ETF
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What Does Downgrade Mean in Investing?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
